Table 2.

Characteristics of metastases by BRAF status.

	BRAF wild-type (N = 39)	BRAF-mutated (N = 30)	p-valuea
Use of WBRT	31 (79%)	13 (43%)	<0.01
GK as initial treatment	14 (36%)	3 (10%)	0.01
GK as salvage treatment after WBRT	17 (44%)	10 (33%)	0.39
Median treatment volume (mL)	2.1 (0.1–284.8)	0.8 (0.1–99.6)	0.45
Median max treatment dimension (cm)	1.0 (0.2–6.2)	0.8 (0.3–2.9)	0.15
Median marginal dose (Gy)	22 (15–24)	22 (12–24)	0.63

^ap-value for between-treatment comparisons. Continuous variables were analyzed by general Wilcoxon test. Categorical variables were analyzed by the Chi-square test.